Prime Medicine, Inc.

NASDAQ:PRME

Biotechnology

Healthcare
$3.82 -1.11%

-$0.04 today

Market cap
$694.94M
Beta
2.31
P/E (TTM)
-2.8
EPS (TTM)
-$1.12
52W Low $1.77High $6.94

Volume 4.62M

Average 2.47M

PRME Pre-Tax Margin

Income before tax as a percentage of revenue.

Prime Medicine, Inc.NASDAQ: PRME

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -5738.6%

Pre-tax margin was -5738.6% in Q1 FY2026, down 2169.8 pp from a year earlier. On a trailing-twelve-month basis it was -4917.6%, up 338.4 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-5738.6%-239.9 pp QoQ
Last fiscal yearDec 2025
-4342.4%+2224.2 pp YoY
LTMMar 2026
-4917.6%+338.4 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2169.8 pp——
1 year+2224.2 pp——
3 years———
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-4342.4%
Year-over-year change
+2224.2pp

Pre-Tax Margin vs competitors

How PRME compares with its peers on the latest reported figures

  • PRME's LTM Mar 2026 pre-tax margin of -4917.6% is the lowest of the 6 companies compared; the peer median is -597.0%.
  • Its year-over-year change of +338.4 pp is the 4th highest of 6, against a peer median of +419.5 pp.
PRME Competitors Peer median
Pre-Tax Margin for PRME and competitors
Company Period LTM level YoY 3-year change
BEAMBeam Therapeutics Inc.LTM Jun 2026-54.7% +606.6 pp+411.7 pp
EDITEditas Medicine, Inc.LTM Mar 2026-281.6% +419.5 pp+723.2 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-597.0% +557.1 pp+299.9 pp
CRBUCaribou Biosciences, Inc.LTM Mar 2026-1194.0% +296.9 pp-615.0 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-1802.2% -515.0 pp+132731.0 pp
PRMEPrime Medicine, Inc.LTM Mar 2026-4917.6% +338.4 pp—
DSGNDesign Therapeutics, Inc.FY2025— ——
SCTXScribe Therapeutics Inc.—— ——
Peer median (excluding PRME) -597.0%+419.5 pp+411.7 pp

Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0002.98M4.63M
Cost of Revenue00007.32M
Gross Profit0002.98M(2.69M)
Gross Margin———100.0%-58.1%
Research & Development70.55M86.73M147.91M155.29M160.64M
Selling, General & Admin13.92M29.82M43.39M50.16M52.35M
Operating Expenses84.47M116.54M204.79M205.45M205.66M
Depreciation & Amortization568K2.22M4.65M6.13M5.38M
EBITDA(165.29M)(120.55M)(186.64M)(189.75M)(195.76M)
EBITDA Margin———-6361.2%-4226.2%
Operating Income(84.47M)(116.54M)(204.79M)(202.47M)(208.35M)
Operating Margin———-6787.4%-4498.1%
Interest Income0003.52M4.15M
Interest Expense00000
Other Income / Expenses(81.38M)(6.23M)6.38M6.59M7.21M
Income Before Tax(165.85M)(122.77M)(198.41M)(195.88M)(201.14M)
Pre-Tax Margin———-6566.6%-4342.4%
Income Tax Expense(486K)(948K)(279K)00
Net Income(165.37M)(121.82M)(198.13M)(195.88M)(201.14M)
Net Margin———-6566.6%-4342.4%
EPS (Basic)(1.92)(1.46)(2.18)(1.65)(1.35)
EPS (Diluted)(1.92)(1.46)(2.18)(1.65)(1.35)
Weighted Avg Shares95.73M97.21M90.97M118.6M148.76M
Weighted Avg Shares (Diluted)95.73M97.21M90.97M118.6M148.76M

Prime Medicine, Inc.

NASDAQ:PRME

Intrinsic Alpha fair value

Locked

Current Price

$3.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.